Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial
Authors' conclusion
Bimagrumab plus semaglutide resulted in substantial reductions in body weight, and safety was consistent with the known safety profiles of both drugs.
Study context
- Population
- Adults with obesity (BMI ≥30 kg m-2 or ≥27 kg m-2 with ≥1 obesity-associated complication, excluding diabetes)randomized to 9 groups
- Participants
- 507 adults
- Comparison
- Bimagrumab, semaglutide and their combinations vs placebo
- Primary endpoint
- Absolute change from baseline in body weight
- Follow-up
- Week 48
Methodological detailsdouble-blind, placebo-controlled, phase 2, stratified by sex, open-label extension to week 72
- Double-blind
- Placebo-controlled
- Phase 2
- Stratified by sex
- Open-label extension to week 72
Primary result
As reported in the abstract
Absolute change in body weight (least squares mean)
Bimagrumab 30 mg kg-1
−9.3
least squares mean · kg
Semaglutide 2.4 mg
−14.2
least squares mean · kg
Bimagrumab 30 mg kg-1 plus semaglutide 2.4 mg
−17.8
least squares mean · kg
Placebo
−3.3
least squares mean · kg
Bimagrumab 30 mg kg-1 vs Placebo: P < 0.001 versus placebo · Semaglutide 2.4 mg vs Placebo: P < 0.001 versus placebo · Bimagrumab 30 mg kg-1 plus semaglutide 2.4 mg vs Placebo: P < 0.001 versus placebo
Secondary outcomes
Absolute change in body weight · week 72
- Continued improvements were observed through week 72
Safety
Common AEs
- Bimagrumab: muscle spasms, diarrhea and acne
- Semaglutide: nausea, diarrhea, constipation and fatigue
- Safety consistent with known safety profiles of both drugs
Original publication
Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial. Nat Med. Published 2 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →